Clinical Trials on FTD in France

Total 9 results

Hopital Lariboisière

Unknown

STD Screening in Women Admitted in Family Planning for a Termination of Pregnancy (DEP-IST-IVG)

STD

France
CerbaXpert

Recruiting

Evaluation of the Physiological Stability Variability and Robustness of NIS4

Evaluate the Physiological Stability of NIS4 Biomarker Between the Fed and Fasting State in Patients With the Target Condition (NAFLD)

France
Hôpital le Vinatier

Recruiting

Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease (Nfl_COG)

Schizophrenia | Alzheimer Disease | Bipolar Disorder | FTD

France
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Social-cognitive Functioning: Validation of a New Neuropsychological Test (REALSOCOG)

Alzheimer's Disease (AD) | Lewy Body Dementia (LBD) | Frontotemporal Degeneration (FTD)

France
French Innovative Leukemia Organisation
Acute Leukemia French Association

Recruiting

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (OGILAR)

AML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITD

France
French Innovative Leukemia Organisation
Acute Leukemia French Association

Completed

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE (ELEGANCE)

Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITD

France
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)

United States, Canada, Germany, Italy, Spain, United Kingdom, France
Novartis Pharmaceuticals

No longer available

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy (AMLFLT3)

Acute Myeloid Leukemia (AML) With | FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom

Clinical Trials on FTD in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations